FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109658051> ?p ?o ?g. }

• W2109658051 endingPage "28" @default.
• W2109658051 startingPage "18" @default.
• W2109658051 abstract "The impact of high-dose therapy and autologous stem cell transplantation (ASCT) vs conventional-dose chemotherapy in the initial management of adults with advanced follicular lymphoma (FL) on overall survival remains uncertain. We performed a systematic review of the randomized clinical trials addressing this question. We searched MEDLINE, EMBASE, CENTRAL, American Society of Hematology, American Society of Clinical Oncology, BIOSIS, PAPERSFIRST, PROCEEDINGS, clinical trials registries, and bibliographies of relevant studies for randomized clinical trials comparing myeloablative chemotherapy with ASCT to any chemotherapy in adults with untreated advanced FL. We performed a meta-analysis using random effects models to estimate overall survival, event-free survival, and risks of adverse outcomes. Statistical heterogeneity was calculated by using the I2 statistic. Seven trials proved eligible, four of which provided data from 941 patients that could be included in a meta-analysis and three of which remain unpublished. In two of the trials, patients in both arms received rituximab during the induction treatment. Moderate quality evidence from the three trials that reported overall survival (n = 701 patients) suggests that ASCT did not result in improved overall survival (hazard ratio of death = 0.99, 95% confidence interval [CI] = 0.73 to 1.33). Low-quality evidence from the four trials of 941 patients suggests improvement in event-free survival in favor of ASCT (hazard ratio of death = 0.54, 95% CI = 0.36 to 0.82) with substantial heterogeneity ( I2 = 80%). Adverse outcomes of treatment-related mortality, myelodysplastic syndrome, acute myeloid leukemia, and solid tumors were not different between the two arms (relative risk [RR] of treatment-related mortality = 1.04, 95% CI = 0.29 to 3.70; RR of myelodysplastic syndrome/acute myeloid leukemia = 2.19, 95% CI = 0.45 to 10.55; I2 = 48%; and RR of solid tumors = 1.30, 95% CI = 0.33 to 5.08). The absolute risk of death from treatment was 14 per 1000 patients for those who received chemotherapy and 15 per 1000 for those who received ASCT (range = 4–52). Available evidence suggests that high-dose therapy and ASCT as part of FL initial treatment does not improve overall survival. Future trials of ASCT in the context of current chemoimmunotherapy approaches to FL are needed." @default.
• W2109658051 created "2016-06-24" @default.
• W2109658051 creator A5031717153 @default.
• W2109658051 creator A5044688594 @default.
• W2109658051 creator A5061856914 @default.
• W2109658051 creator A5083858828 @default.
• W2109658051 creator A5084323572 @default.
• W2109658051 date "2011-12-21" @default.
• W2109658051 modified "2023-10-05" @default.
• W2109658051 title "Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis" @default.
• W2109658051 cites W1912693401 @default.
• W2109658051 cites W1965443286 @default.
• W2109658051 cites W1969582706 @default.
• W2109658051 cites W1972822547 @default.
• W2109658051 cites W2037252592 @default.
• W2109658051 cites W2053154970 @default.
• W2109658051 cites W2054312534 @default.
• W2109658051 cites W2067618106 @default.
• W2109658051 cites W2071710566 @default.
• W2109658051 cites W2075141373 @default.
• W2109658051 cites W2075642745 @default.
• W2109658051 cites W2088095316 @default.
• W2109658051 cites W2089283250 @default.
• W2109658051 cites W2105397991 @default.
• W2109658051 cites W2106756881 @default.
• W2109658051 cites W2115878443 @default.
• W2109658051 cites W2126027842 @default.
• W2109658051 cites W2135321054 @default.
• W2109658051 cites W2138498369 @default.
• W2109658051 cites W2138881579 @default.
• W2109658051 cites W2152996672 @default.
• W2109658051 cites W2156522119 @default.
• W2109658051 cites W2161609099 @default.
• W2109658051 cites W2165010366 @default.
• W2109658051 cites W2165254830 @default.
• W2109658051 cites W2169578616 @default.
• W2109658051 cites W4211087034 @default.
• W2109658051 cites W4293203547 @default.
• W2109658051 doi "https://doi.org/10.1093/jnci/djr450" @default.
• W2109658051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22190633" @default.
• W2109658051 hasPublicationYear "2011" @default.
• W2109658051 type Work @default.
• W2109658051 sameAs 2109658051 @default.
• W2109658051 citedByCount "69" @default.
• W2109658051 countsByYear W21096580512012 @default.
• W2109658051 countsByYear W21096580512013 @default.
• W2109658051 countsByYear W21096580512014 @default.
• W2109658051 countsByYear W21096580512015 @default.
• W2109658051 countsByYear W21096580512016 @default.
• W2109658051 countsByYear W21096580512017 @default.
• W2109658051 countsByYear W21096580512018 @default.
• W2109658051 countsByYear W21096580512019 @default.
• W2109658051 countsByYear W21096580512020 @default.
• W2109658051 countsByYear W21096580512021 @default.
• W2109658051 countsByYear W21096580512022 @default.
• W2109658051 countsByYear W21096580512023 @default.
• W2109658051 crossrefType "journal-article" @default.
• W2109658051 hasAuthorship W2109658051A5031717153 @default.
• W2109658051 hasAuthorship W2109658051A5044688594 @default.
• W2109658051 hasAuthorship W2109658051A5061856914 @default.
• W2109658051 hasAuthorship W2109658051A5083858828 @default.
• W2109658051 hasAuthorship W2109658051A5084323572 @default.
• W2109658051 hasConcept C126322002 @default.
• W2109658051 hasConcept C141071460 @default.
• W2109658051 hasConcept C143998085 @default.
• W2109658051 hasConcept C168563851 @default.
• W2109658051 hasConcept C197934379 @default.
• W2109658051 hasConcept C207103383 @default.
• W2109658051 hasConcept C2777058707 @default.
• W2109658051 hasConcept C2779050716 @default.
• W2109658051 hasConcept C2779338263 @default.
• W2109658051 hasConcept C2911091166 @default.
• W2109658051 hasConcept C44249647 @default.
• W2109658051 hasConcept C535046627 @default.
• W2109658051 hasConcept C71924100 @default.
• W2109658051 hasConcept C95190672 @default.
• W2109658051 hasConceptScore W2109658051C126322002 @default.
• W2109658051 hasConceptScore W2109658051C141071460 @default.
• W2109658051 hasConceptScore W2109658051C143998085 @default.
• W2109658051 hasConceptScore W2109658051C168563851 @default.
• W2109658051 hasConceptScore W2109658051C197934379 @default.
• W2109658051 hasConceptScore W2109658051C207103383 @default.
• W2109658051 hasConceptScore W2109658051C2777058707 @default.
• W2109658051 hasConceptScore W2109658051C2779050716 @default.
• W2109658051 hasConceptScore W2109658051C2779338263 @default.
• W2109658051 hasConceptScore W2109658051C2911091166 @default.
• W2109658051 hasConceptScore W2109658051C44249647 @default.
• W2109658051 hasConceptScore W2109658051C535046627 @default.
• W2109658051 hasConceptScore W2109658051C71924100 @default.
• W2109658051 hasConceptScore W2109658051C95190672 @default.
• W2109658051 hasIssue "1" @default.
• W2109658051 hasLocation W21096580511 @default.
• W2109658051 hasLocation W21096580512 @default.
• W2109658051 hasOpenAccess W2109658051 @default.
• W2109658051 hasPrimaryLocation W21096580511 @default.
• W2109658051 hasRelatedWork W1900595920 @default.
• W2109658051 hasRelatedWork W2130616545 @default.
• W2109658051 hasRelatedWork W2194631636 @default.

• next